Literature DB >> 26160625

Treatment of Hypertension: Favourable Effect of the Twice-Daily Compared to the Once-Daily (Evening) Administration of Perindopril and Losartan.

Ipoly Szauder1, Eszter Csajági, Zsuzsanna Major, Gabor Pavlik, Gabriella Ujhelyi.   

Abstract

BACKGROUND/AIMS: Little is known about the effect of twice daily administration of same dose of ACE inhibitor and ARB on the diurnal/nocturnal blood pressure (BP) ratio. We aimed to assess the effect of two widely used long-acting drugs: perindopril and losartan in the treatment of hypertension comparing the once-daily (evening) vs. twice-daily (morning and evening) administration with the same daily doses.
METHODS: Untreated primary hypertensive patients without complaints (a total of 164: 65 men, 99 women, 55.7 ± 13.7 years of age, 41-41 patients per treated groups) were selected with non-dipper phenomenon, estimated by diurnal index (DI) <10%. The effect of evening (8 mg perindopril or 100 mg losartan) vs morning and evening (4-4 mg perindopril or 50-50 mg losartan) administration was determined on a 14-day treatment by ABPM.
RESULTS: The mean BP, the percent time elevation index, and the hyperbaric impact decreased in both drug groups. Significant difference was observed in the DI in the case of twice-daily administration vs once-daily evening dosing.
CONCLUSIONS: The twice-daily administration with the same daily dose of perindopril or losartan seems to be more effective compared to the once daily evening administration in eliminating the non-dipper phenomenon. According to some authors the non-dipping phenomenon increases cardiovascular risk, while others are of the opinion that the association of non-dipping with cardiovascular events does not necessarily mean that selective treatment of non-dipping improves cardiovascular outcomes.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26160625     DOI: 10.1159/000368513

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  5 in total

Review 1.  Chronotherapy for Hypertension.

Authors:  N P Bowles; S S Thosar; M X Herzig; S A Shea
Journal:  Curr Hypertens Rep       Date:  2018-09-28       Impact factor: 5.369

2.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

3.  SuperDRUG2: a one stop resource for approved/marketed drugs.

Authors:  Vishal B Siramshetty; Oliver Andreas Eckert; Björn-Oliver Gohlke; Andrean Goede; Qiaofeng Chen; Prashanth Devarakonda; Saskia Preissner; Robert Preissner
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

4.  Role of miR-128 in hypertension-induced myocardial injury.

Authors:  Jie Yin; Hongyan Liu; Lei Huan; Suping Song; Liying Han; Faxin Ren; Zengtang Zhang; Zhiqiang Zang; Junye Zhang; Shu Wang
Journal:  Exp Ther Med       Date:  2017-08-04       Impact factor: 2.447

5.  Clinical Utility of 24-h Ambulatory Blood Pressure Monitoring in Hospitalized Patients with Chronic Kidney Disease.

Authors:  Santosh B Salagre; Nigarbi N A Ansari; Vandana S Mali
Journal:  Indian J Nephrol       Date:  2021-02-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.